IL-12 augments antitumor responses to cycled chemotherapy

Journal of Immunotherapy

Volumn 38, Issue 4, 2015, Pages 137-144

  Zhang, Lingbing ^a   Feng, Dongdong ^a   Hu, Yingbin ^a,b   Tsung, Kangla ^a   Norton, Jeffrey A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

antitumor immunity; cycled chemotherapy; IL 12

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 12; IMMUNOLOGICAL ADJUVANT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; LYMPHOCYTIC INFILTRATION; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; SINGLE DRUG DOSE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MODEL; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CANCER TRANSPLANTATION; CELLULAR IMMUNITY; CYTOTOXICITY; DRUG EFFECTS; DRUG RESISTANCE; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASMS; RECURRENT DISEASE; TUMOR CELL LINE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNITY, CELLULAR; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECURRENCE;

EID: 84928492096     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000074     Document Type: Article

References (43)

1. Morgan G, Ward R, Barton M. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2004; 16: 549-560.
2. Chabner BA, Roberts TG Jr. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer. 2005; 5: 65-72.
3. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol. 2005; 205: 275-292.
4. Keating P, Cambrosio A, Nelson NC, et al. Therapy's shadow: a short history of the study of resistance to cancer chemotherapy. Front Pharmacol. 2013; 4: 58.
5. M.Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002; 53: 615-627.
6. Holohan C, Van Schaeybroeck S, Longley DB, et al. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013; 13: 714-726.
7. Rebucci M, Michiels C. Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol. 2013; 85: 1219-1226.
8. Coley HM. Overcoming multidrug resistance in cancer: clinical studies of p-glycoprotein inhibitors. Methods Mol Biol. 2010; 596: 341-358.
9. Szakács G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5: 219-234.
10. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 2009; 14: 3-9.
11. MDean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5: 275-284.
12. Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 2010; 143: 355-366.
13. Sun Y, Campisi J, Higano C, et al. Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med. 2012; 18: 1359-1368.
14. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004; 21: 137-148.
15. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007; 117: 1137-1146.
16. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008; 118: 1991-2001.
17. Lake RA, Robinson BW. Immunotherapy and chemotherapy- a practical partnership. Nat Rev Cancer. 2005; 5: 397-405.
18. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007; 13: 1050-1059.
19. Tong Y, Song W, Crystal RG. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 2001; 61: 7530-7535.
20. Yu B, Kusmartsev S, Cheng F, et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res. 2003; 9: 285-294.
21. Ikitina EY, Gabrilovich DI. Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer. 2001; 94: 825-833.
22. Udagawa M, Kudo-Saito C, Hasegawa G, et al. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation. Clin Cancer Res. 2006; 12: 7465-7475.
23. Zhang L, Feng D, Yu LX, et al. Preexisting antitumor immunity augments the antitumor effects of chemotherapy. Cancer Immunol Immunother. 2013; 62: 1061-1071.
24. Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993; 178: 1223-1230.
25. Tahara H, Zeh HJ 3rd, Storkus WJ, et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res. 1994; 54: 182-189.
26. Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol. 1995; 155: 1393-1403.
27. Zou JP, Yamamoto N, Fujii T, et al. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: response is correlated with a striking reversal of suppressed IFN-gamma production by anti-tumor T cells. Int Immunol. 1995; 7: 1135-1145.
28. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997; 90: 2541-2548.
29. Le HN, Lee NC, Tsung K, et al. Pre-existing tumor-sensitized T cells areessential for eradication of established tumors by IL- 12 and cyclophosphamide plus IL-12. J Immunol. 2001; 167: 6765-6772.
30. Robertson MJ, Cameron C, Atkins MB, et al. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res. 1999; 5: 9-16.
31. Motzer RJ, Rakhit A, Thompson JA, et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res. 2001; 21: 257-263.
32. Tsung K, Meko JB, Tsung YL, et al. Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12. J Immunol. 1998; 160: 1369-1377.
33. Desai BB, Quinn PM, Wolitzky AG, et al. IL-12 receptor. II. Distribution and regulation of receptor expression. J Immunol. 1992; 148: 3125-3132.
34. Reddy M, Wong J, Davis C, et al. Co-expression of IL-12 receptors along with CXCR3 and CD25 on activated peripheral blood T lymphocytes. Cell Immunol. 2005; 236: 123-130.
35. Ruby CE, Montler R, Zheng R, et al. IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol. 2008; 180: 2140-2148.
36. Tsung K, Dolan JP, Tsung YL, et al. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 2002; 62: 5069-5075.
37. King IL, Segal BM. Cutting edge: IL-12 induces CD4+ CD25- T cell activation in the presence of T regulatory cells. J Immunol. 2005; 175: 641-645.
38. Prochazkova J, Pokorna K, Holan V. IL-12 inhibits the TGFb- dependent T cell developmental programs and skews the TGF-b-induced differentiation into a Th1-like direction. Immunobiology. 2012; 217: 74-82.
39. Gerner MY, Heltemes-Harris LM, Fife BT, et al. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol. 2013; 191: 1011-1015.
40. Kerkar SP, Leonardi AJ, van Panhuys N, et al. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther. 2013; 21: 1369-1377.
41. Steding CE, Wu ST, Zhang Y, et al. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology. 2011; 133: 221-238.
42. Iigo M, Tsuda H, Moriyama M. Enhanced therapeutic effects of anti-tumour agents against growth and metastasis of colon carcinoma 26 when given in combination with interferon and interleukin-2. Clin Exp Metastasis. 199; 12: 368-374.
43. Gomez GG, Hutchison RB, Kruse CA. Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Cancer Treat Rev. 2001; 27: 375-402.